Launching the Industry Advisory Council
On 23rd February 2016, under the leadership of Mike Zelin, the ARC’s Director of Industry Relations, we held the first meeting of the ARC Industry Advisory Council.
This groundbreaking meeting brought together key leaders from seven pharmaceutical companies. These companies are all developing novel therapies for amyloidosis. The meeting goals were to establish the areas of research and investigations that can be better realized through collaboration. ARC is committed to accelerating research and creating efficiencies; these industry partnerships are essential to realizing these goals.
The meeting was a resounding success. Robust discussions led to a commitment to work together on a number of initiatives. We look forward to supporting the development of more amyloidosis programs as a result, and ongoing meetings of the Industry Advisory Council.
- Categories
- Lastest Posts
- FDA Approves Attruby™ (acoramidis) for the Treatment of ATTR-CM: A New Option for Patients
- ARC Launches Clinical Fellowship Program to Advance Amyloidosis Care
- The More Things Change, the More They Stay the Same
- The Inflation Reduction Act: The Devil is in the Details for Patients with Rare Diseases
